The invention discloses a thermosensitive modified chitin hydrogel local anesthetic-loaded sustained-release analgesia system, a preparation method and use. A thermosensitive chitin derivative is dissolved into water at a low temperature, a local anesthetic and analgesic drug aqueous solution or degradable polymer microspheres loaded with local anesthetic and analgesic drugs are added under a liquid state, the above materials are evenly mixed at a low temperature, the obtained mixture is injected into a site needing local anesthesia and analgesia so as to quickly form a gel under a body temperature and release the drug. The local anesthetic drug sustained-release analgesia composite hydrogel system is mainly characterized in that preparation is simple, organic solvents are not used, the local anesthetic and analgesic drug can be slowly released, and the problems that the existing local anesthetic drugs have a short action time are solved partly.

A process for preparing a powder for reconstitution as a suspension includes the following steps: First, complexing Valaciclovir with an ion exchange resin and forming Drug-Resin complex (DRC) particles. The complexing includes Dry blending of Drug:Ion Exchange Resin in a ratio 1:0.8 to form a blend; Kneading the blend with water in a ratio of Drug:Ion Exchange Resin:Water 1:0.8:0.5 to form a wet mass; Drying of the wet mass at 40° C.
Next, milling of the Drug-Resin complex particles until particle size gets less than 250 μm, and then dry mixing of the Drug-Resin complex particles with excipients to form an internal phase. The excipients of the internal phase comprise a suspending agent and a pH agent, and the suspending agent forms a film around each DRC particle and the film decreases interparticle attraction. Next, mixing the internal phase with excipients of an external phase to form the powder, and then sifting the powder to eliminate any clumps.

Provided herewith is a pharmaceutical composition comprising, separately or together, a pulsatile release component comprising levodopa and a DOPA decarboxylase inhibitor for the management of OFF-time episodes in patients with Parkinson's disease.

The present invention provides a composition based on cannabidiol (CBD) and chitosan for use in reducing blood cholesterol, blood LDL and blood triglycerides levels.

The present invention relates to a solid pharmaceutical preparation of 3-Fluoro-4-[7-methoxy-3-methyl-8-(1-methyl-1H-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl]-benzonitrile, a method of making same, and medical uses thereof.

Provided are a novel amorphous curcumin compound powdery composition that is inexpensive, is improved in bioabsorbability and bioavailability of curcumin, and has long-term stability, and a method for producing the powdery composition.

The present invention relates to a powdery composition containing an amorphous curcumin compound and a hydrophilic modified starch and having a Raman spectrum including one or more peaks at wavenumbers of 1630, 1599, 1428, and 1243 (expressed in ±2 cm.sup.−1) and a method for producing the powdery composition.

The present invention relates to the technical field of medicine and relates to an instant release pharmaceutical preparation of an anticoagulant and a preparation method therefor. The instant release pharmaceutical preparation of an anticoagulant comprises a vicagrel compound or a pharmaceutically acceptable form thereof, the preparation is a tablet or a capsule, the vicagrel or the pharmaceutically acceptable form thereof is provided at a suitable particle size, and the D90 thereof <50 μm. With regard to the drug-containing particles obtained by the present invention, a pharmaceutical preparation formed therefrom exhibits rapid release characteristics in an in vitro dissolution test and exhibits considerable advantages in pharmacokinetics in vivo, showing a greater degree (AUC) and rate (C.sub.max) of drug absorption. Further provided by the present invention is a method for preparing an instant release pharmaceutical preparation of an anticoagulant; according to the formulation of the drug-containing particles as disclosed by the present invention, a capsule or tablet instant release preparation having excellent stability may be obtained by means of a combination of optional preparation steps.

An ingestible particle comprising sodium bicarbonate, wherein the particle has size in the range of more than 1.0 mm but not more than 5.0 mm, with a thickness in at least one dimension of more than 1.0 mm but not more than 2.0 mm; and wherein the particle contains more than 50% (w/w) of the sodium bicarbonate. The ingestible particles are comprised in a nutritional supplement composition which is a suspension comprising the ingestible particles dispersed in an aqueous liquid, preferably a viscous aqueous medium.

One of the problems of one embodiment of the present invention is to provide film-coated granules which have a new film constitution. Alternatively, one of the problems of one embodiment of the present invention is to provide a pharmaceutical preparation containing the film-coated granules which have a new film constitution. Alternatively, one of the problems of one embodiment of the present invention is to provide a new dry manufacturing method of the film-coated granules. Alternatively, one of the problems of one embodiment of the present invention is to provide a new dry manufacturing method of the pharmaceutical preparation containing the film-coated granules. According to one embodiment of the present invention, a film-coated granule is provided that comprises a core particle having a melt component, and a film arranged on a surface of the core particle, wherein the film includes a porous substance, a plasticizer and a polymer.

An inhalable microparticles having cysteamine hyaluronate salt is provided. Also a preparation method and a pharmaceutical composition thereof are provided.